[Experimental study of radioimmunotherapy for xenograft of human esophageal carcinoma]

Using nude mice bearing human esophageal carcinoma strain Eca 109 as models of tumor, we tested the therapeutic efficiency of 131I labelled monoclonal antibody MGb2 A 4-week experimental study was carried out in 5 treatment groups: group A, buffer, group B, unlabelled MGb2; group C, 131I-labelled normal mice IgG and group D, 131I-labelled MGb2 18.5MBq. All nude mice above were given agents intraperitoneally. In group E, the animals were given 131I-labelled MGb2 18.5MBq by intratumoral administration. The results showed that from the second week, in group D and E the tumor volume was remarkably decreased as compared with that of the other 3 groups (P < 0.01 or P < 0.05). In the fourth week the mean volume in group D and E were 0.55 cm3 and 0.23cm3, while in group A, the volume was 1.43cm3. The inhibition rate of tumor growth in group D and E was higher than in other groups from the second week (P < 0.01), especialy in the third and fourth week with a mean value of 62. 4%, 61.5% and 82.2%, 83.9% respectively. There were no significant differences between group A, B, and C in tumor volume or growth inhibition rate.